期刊文献+

欧美药物警戒中电子化医疗保健数据的应用研究 被引量:9

Study on Application of Electronic Healthcare Records in Pharmacovigilance in US and EU
下载PDF
导出
摘要 目的为进一步促进我国药品不良反应监测工作提供思路和参考。方法研究国外利用电子化医疗保健数据开展药物警戒工作的现状和具体应用,归纳与分析其中的不足,为基于我国医院信息系统开展药品不良反应监测、上市后临床研究提出建议。结果与结论利用电子化医疗保健数据开展药品不良反应监测与药物警戒可以从真实世界获取数据,在源头提高报告质量、减少漏报;加强主动监测可以弥补自发报告的不足,是提升工作质量和工作价值的良好途径;应借鉴国外先进经验与技术,加强我国医院信息系统建设与信息综合利用。 Objective To provide thought and references for the promotion of ADR monitoring in China. Methods Study on the current state and the practical application by using of data from electronic healthcare records for pharmacovigilance. The shortcomings were summarized and analyzed, suggestions on improving ADR monitoring and post-marketing clinical studies were put forward based on HIS. Results&Conclusion It can get data from the real world to carry out the ADR monitoring by using the HIS, improving the quality of ADR reporting at source and reducing the omission.To strengthen active surveillance can make up for the inadequacy of spontaneous reporting. It is a good way to improve the quality and the value of ADR monitoring. We should draw lessons from foreign advanced experience and technology, strengthen the HIS construction and information comprehensive utilization.
作者 王玲
出处 《中国药物警戒》 2015年第3期156-159,共4页 Chinese Journal of Pharmacovigilance
关键词 药品不良反应 电子化医疗保健数据 药物警戒 医院信息系统 adverse drug reaction electronic healthcare records pharmacovigilance hospital information system
  • 相关文献

参考文献23

  • 1CFDA.药品不良反应报告和监测管理办法(卫生部令第8l号)[EB/OL].(2011-05-04)[2012-10-06].http://www.sda.gov.cn/WS01/CL0053/62621.html.
  • 2王玲,周晶鑫,张学宁,蔺旭东.药品不良反应报告数据规整的实践与思考[J].中国药物警戒,2014,11(7):407-412. 被引量:10
  • 3Robb M A,Racoosin J A,Sherman R,et al.The US Food and Drug Administration's Sentinel Initiative:Expanding the horizons of medical product safety[J].Pharmacoepidemiology and Drug Safety, 2012,21($1 ) :9-11.
  • 4周晓枫,刘青,蔡兵,Andrew Bate.全球上市后药品主动监测系统概况[J].药物流行病学杂志,2012,21(7):338-342. 被引量:9
  • 5Stang P E,Ryan P B,Racoosin J A,et al. Advancing the science for active surveillance:rationale and design for the Observational Medical Outcomes Partnershop[J]. Annals of Internal Medicine, 2010,153 (9):600-606.
  • 6蔡兵,刘青,周晓枫,Andrew Bate.药品安全主动监测方法简介[J].药物流行病学杂志,2013,22(8):439-443. 被引量:8
  • 7Takahashi Y24ishida Y,Asai S. Utilization of health care databases for Pharmacoepidemiology[J].Eur J Clin Pharmacol, 2012,68(2 ):123-129.
  • 8Michael D Murray.Use of Data from Electronic Health Records for pharmacoepidemiology [J].Curr Epidemiol Pep, 2014,1:186-193.
  • 9Hennessy S.Use of health care databases in pharmacoepidemiology [J]. Basic & Clinical Pharmacology & Toxicology, 2006,98,311-313.
  • 10FDA.Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five Year Plan[EB/OL]. (2010-06) [2014-12-23].www.fda.gov/ downloads/forindustry/userfees/prescriptiondruguserfee/ucm- 216354.pdf.

二级参考文献79

  • 1句华.英国NHS内部市场的实践及其启示[J].中共福建省委党校学报,2005(7):77-80. 被引量:4
  • 2纪立伟,李可欣,傅得兴.222份药品不良反应报告表质量评价[J].药物不良反应杂志,2005,7(6):458-460. 被引量:11
  • 3曾国经.英国的全科医疗与初级保健护理[J].中国农村卫生事业管理,2006,26(1):66-68. 被引量:5
  • 4王晓瑜,杜文民,王宏敏,徐建龙.2005年上海市药品不良反应自发报告质量评价[J].中国临床药学杂志,2006,15(5):331-333. 被引量:23
  • 5Storm BL. Pharmacoepidemiology [ M ]. 3rd ed. West Sus- sex :John Wiley & Sons Ltd, 2000. 149-387.
  • 6Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for Pharmacoepidemiology [ J ]. Eur J Clin Phar- macol, 2011, Epub ahead of print.
  • 7Hennessy S. Use of health care databases in Pharmacoepide- miology [ J ]. Basic Clin Pharmacol Toxicol , 2006, 98 ( 3 ) : 311-313.
  • 8Mann RD, Andrews EB. Pharmacovigilance [ M ]. 2nd ed. West Sussex:John Wiley & Sons Ltd, 2007. 341-373.
  • 9Wysowski DK. Reports of esophageal cancer with oral bi- sphosphonate use [J]. N Engl J Med, 2009, 360:89-90.
  • 10Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer [ J ]. JA- MA, 2010, 304:657-663.

共引文献30

同被引文献115

引证文献9

二级引证文献117

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部